Skip to main content

Table 5 Baseline Demographics and Illness Severity for Predicted Outcome Groups

From: Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia

 

Likely Responders

Likely Non-responders

Not Predictable

p-valuea

n (%)

445/1494 (29.8)

929/1494 (62.2)

120/1494 (8.0)

 

Age in years, mean (SD)

39.1 (11.1)

40.4 (10.6)

38.9 (10.4)

.06

Female gender, n (%)

167 (37.5)

295 (31.8)

51 (42.5)

.02

Ethnicity/Race, n (%)

    

   White

219 (49.2)

474 (51.0)

56 (46.7)

.53

   Black

141 (31.7)

309 (33.3)

43 (35.8)

 

   Hispanic

85 (19.1)

146 (15.7)

21 (17.5)

 

Diagnosis, n (%)

    

   Schizophrenia

345 (77.5)

743 (80.0)

101 (84.2)

.26

   Schizoaffective disorder

95 (21.3)

186 (20.0)

18 (15.0)

.31

   Schizophreniform disorder

5 (1.1)

0 (0.0)

1 (0.8)

.003

Age at illness onset in years, mean (SD)

23.8 (8.8)

23.4 (8.3)

23.0 (7.4)

.53

Duration of illness in years, mean (SD)

15.3 (10.9)

17.0 (10.7)

15.9 (10.5)

.02

Number of prior episodes, median

5

6

5

 

PANSS Total score, mean (SD)

101.5 (16.1)

95.4 (14.0)

101.9 (17.3)

<.001

PANSS Positive score, mean (SD)

25.6 (5.1)

23.5 (4.2)

26.1 (4.7)

<.001

PANSS Negative score, mean (SD)

26.0 (5.9)

24.9 (5.5)

25.4 (6.0)

.002

CGI-S score, mean (SD)

4.8 (0.8)

4.7 (0.7)

4.8 (0.7)

<.001

Weight in kg, mean (SD)

83.0 (22.9)

84.9 (20.5)

82.6 (22.0)

.24

  1. Abbreviations: CGI-S = Clinical Global Impression-Severity23; n = number in group; PANSS = Positive and Negative Syndrome Scale13; SD = standard deviation.
  2. aComparisons based on analysis of variance (ANOVA) and the Cochran-Mantel-Haenszel test accounting for study effect.